Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the completion of dosing for the first cohort of subjects in its Phase 1/2 trial of lead candidate, VIO-01, a pan-DDR decoy for the treatment of solid tumors. VIO-01 is the next-generation DNA decoy generated from Valerio Therape